Ion Exchange Patents (Class 530/416)
  • Patent number: 11884698
    Abstract: Embodiments of the present disclosure are directed to methods for preparing a target polypeptide from a mixture including the target polypeptide. The method may include contacting the mixture to a hydrophobic interaction chromatography (HIC) apparatus including multiple chromatographic zones. The method may further include passing the target polypeptide through the outlets of at least a first zone and a second zone of the HIC apparatus. A residence time for the mixture including the target polypeptide in a first zone may be approximately the same as a residence time of one or more mobile phases in the second zone.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: January 30, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Isabelle Livigni, Stefanie McDermott, James Reilly, John Mattila
  • Patent number: 11807666
    Abstract: The present invention relates to the field of chromatography. More closely, the invention relates to a chromatographic method for purification of proteins, such as Factor VIII, von Willebrand factor and Factor IX. The chromatographic method is performed on a matrix comprising an inner porous core and outer porous lid surrounding said core.
    Type: Grant
    Filed: November 29, 2022
    Date of Patent: November 7, 2023
    Assignee: Cytiva BioProcess R&D AB
    Inventors: Martin Hall, Karolina Busson, Jean-Luc Maloisel, Helena Skoglar
  • Patent number: 11702639
    Abstract: In accordance with the invention, provided herein are methods for purifying recombinant adeno-associated (rAAV) vector particles.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: July 18, 2023
    Inventors: Guang Qu, Younghoon Oh, Lin Lu, John Fraser Wright
  • Patent number: 11697672
    Abstract: The present invention relates to a purification process of recombinant antibody fragments from inclusion bodies expressed in microbial cells. More particularly, the present invention relates to a process for purification of recombinant humanized (rHu) antibody fragment, Ranibizumab from inclusion bodies expressed in microbial cells.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: July 11, 2023
    Assignee: Council of Scientific & Industrial Research
    Inventors: Rahul Sharad Bhambure, Kayanat Mahammadtaki Gani
  • Patent number: 11479593
    Abstract: Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.
    Type: Grant
    Filed: October 27, 2021
    Date of Patent: October 25, 2022
    Assignee: Applied Molecular Transport Inc.
    Inventors: Derek Maclean, Randall J. Mrsny, Kevin Yin, Tahir Mahmood, Bittoo Kanwar, Sally Postlethwaite, Weijun Feng, Sean Dalziel, Hyojin Kim, Rajendra Tandale, Marvin Garovoy, John Koleng
  • Patent number: 11234445
    Abstract: The present invention relates to compositions and methods for modulating or detecting allergy in a subject. The invention may be used to reduce allergenicity of compositions, such as food products, or to stimulate immunogenicity of products, such as vaccines by removal of cationic proteins resulting from transcription infidelity. The invention may be used in any mammal such as human.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: February 1, 2022
    Assignee: GENCLIS
    Inventors: Bernard Bihain, Virginie Ogier, Marie Brulliard, Sandrine Jacquenet, Benoit Thouvenot, Olivier Roitel
  • Patent number: 10934340
    Abstract: The present invention relates to a method for separating a mature von Willebrand Factor (mat-VWF) from von Willebrand Factor pro-peptide (VWF-PP) by incubating a composition comprising inducing dissociation of mat-VWF and VWF-PP by disruption of the non-covalently associated mat-VWF and VWF-PP, wherein said dissociation is induced by: (i) addition of at least one chelating agent, or (ii) increasing the pH to a pH of at least 7, and then collecting said mat-VWF to obtain a high purity, propeptide depleted mature VWF (mat-VWF).
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: March 2, 2021
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Christian Fiedler, Meinhard Hasslacher, Christa Mayer
  • Patent number: 9661868
    Abstract: The present disclosure relates to improved expanded bed adsorption processes for isolating proteins from milk sources. In particular embodiments, the present disclosure provides a process for isolating a milk protein, such as lactoferrin, from a milk source comprising establishing an expanded bed adsorption column comprising a particulate matrix, applying a milk source to the matrix, and eluting the lactoferrin from the matrix with an elution buffer comprising about 0.3 to about 2.0 M sodium chloride.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: May 30, 2017
    Assignee: Mead Johnson Nutrition Company
    Inventors: Dattatreya Banavara, John D. Alvey, Joseph Andrew Peters, Juan M. Gonzalez
  • Patent number: 9493548
    Abstract: The current invention reports a method for purifying an immunoglobulin, wherein the method comprises applying an aqueous, buffered solution comprising an immunoglobulin in monomeric and in aggregated form to a cation exchange material under conditions whereby the immunoglobulin in monomeric form does not bind to the cation exchange material, and recovering the immunoglobulin in monomeric form from the solution after the contact with the cation exchange material.
    Type: Grant
    Filed: May 28, 2008
    Date of Patent: November 15, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roberto Falkenstein, Claudia Giessel
  • Patent number: 9182396
    Abstract: A method for treating an individual at risk for a complement-associated disorder is provided, including: (a) obtaining a sample of a body fluid from the individual; (b) measuring a complement activation level in the sample via a point-of-care lateral flow immunoassay; (c) correlating the complement activation level in the sample to a risk of a complement-associated disorder by comparing the complement activation level in the sample to a reference level in a control, wherein a deviation in complement activation level in the sample compared to the reference level in the control indicates the individual is at risk for a complement-associated disorder; (d) selecting a treatment for the individual, based on the correlating of step (c); and (e) treating the individual with the treatment selected in accordance with step (d). Lateral flow immunoassays and a method of monitoring an individual suffering from a complement-associated disorder are also provided herein.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: November 10, 2015
    Assignee: Kypha, Inc.
    Inventors: Paul Olson, Don W. Moss
  • Patent number: 9078859
    Abstract: The invention relates to the use of a synergistic combination of at least one ion selected from the group including hypothiocyanites and/or hypohalites and of lactoferrin for preparing a pharmaceutical composition for treating cystic fibrosis. In one embodiment, the lactoferrin is one having a purity higher than 95% and substantially free of lipopolysaccharides, endotoxins, and angiogenins, and having an iron saturation level higher than 15%.
    Type: Grant
    Filed: January 28, 2010
    Date of Patent: July 14, 2015
    Assignee: ALAXIA
    Inventors: Philippe Bordeau, Jean-Paul Perraudin
  • Patent number: 9035031
    Abstract: The present invention relates to isolation of whey proteins and the preparation of a whey product and a whey isolate. In particular the present invention relates to the isolation of a ?-lactoglobulin product and the isolation of an ?-enriched whey protein isolate from whey obtained from an animal. The ?-enriched whey protein isolate provided by the present invention is besides from being low in ?-lactoglobulin also high in ?-lactalbumin and immunoglobulin G.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: May 19, 2015
    Inventors: Marie Bendix Hansen, Allan Otto Fog Lihme, Malene Fog Lihme
  • Patent number: 9029517
    Abstract: Adsorptive media for chromatography, particularly ion-exchange chromatography, derived from a shaped fiber. In certain embodiments, the functionalized shaped fiber presents a fibrillated or ridged structure which greatly increases the surface area of the fibers when compared to ordinary fibers. Also disclosed herein is a method to add surface pendant functional groups that provides cation-exchange or anion-exchange functionality to the high surface area fibers. This pendant functionality is useful for the ion-exchange chromatographic purification of biomolecules, such as monoclonal antibodies (mAbs).
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: May 12, 2015
    Assignee: EMD Millipore Corporation
    Inventors: David Yavorsky, John Amara, Joaquin Umana, William Cataldo, Mikhail Kozlov, Matthew Stone
  • Patent number: 9023994
    Abstract: The invention relates to an immunoglobulin composition reduced in thrombogenic agents and to methods for its preparation. One method comprises subjecting an immunoglobulin containing solution to a negative cation exchanger chromatography at a pH in the range of higher than 3.8 to equal to or lower than 5.3. The solution can also be subjected to a negative anion exchanger chromatography at a pH in the range of 7 to 8.2.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: May 5, 2015
    Assignee: Omrix Biopharmaceuticals, Ltd.
    Inventors: Roni Mintz, Oleg Belyaev, Israel Nur, Liliana Bar, Roberto Meidler
  • Patent number: 9012212
    Abstract: A method and system is provided for yielding biopharmaceutical products involving a chromatographic separation process. The method comprises: providing a plurality of membrane adsorber cartridges; providing a plurality of valves, communicatively coupled to said plurality of membrane adsorber cartridges; and switching the valves, so as to interconnect said membrane adsorber cartridges to operate in a countercurrent flow mode. The system comprises multiple membrane adsorber cartridges that are interconnected and configured to operate in a countercurrent flow mode. Furthermore, the configuration comprises a valve assembly that allows the cartridges to be subjected to different steps in the process by automatic switching of the valves. In this way, cartridges are recycled many times during the purification of a batch.
    Type: Grant
    Filed: April 17, 2007
    Date of Patent: April 21, 2015
    Assignee: Xendo Holding B.V.
    Inventors: Marc Antonius Theodorus Bisschops, Jozef Anton Mari Pennings, Jacob Arthur Tijsterman
  • Publication number: 20150093800
    Abstract: The present invention provides methods for cleaning or regenerating a chromatography materiel for reuse. The methods of the invention can be used for cleaning or regenerating chromatography columns for reuse in the large-scale manufacture of multiple polypeptide products.
    Type: Application
    Filed: September 5, 2014
    Publication date: April 2, 2015
    Inventors: Ekta MAHAJAN, Kapil KOTHARY, Joanna SO, Jay WERBER
  • Publication number: 20150065696
    Abstract: The invention is directed to an apparatus and method for purifying a protein. The apparatus involves the use of a capture chromatography resin, a depth filter arranged after the capture chromatography resin, and a mixed-mode chromatography resin arranged after the depth filter. The method involves providing a sample containing the protein, processing the sample through a capture chromatography resin, a depth filter, and a mixed-mode chromatography resin. A membrane adsorber or monolith may be substituted for the mixed-mode chromatography column.
    Type: Application
    Filed: June 4, 2014
    Publication date: March 5, 2015
    Inventors: Chen Wang, Robert K. Hickman, I, Edwin O. Lundell, Roy D. Hegedus
  • Patent number: 8969532
    Abstract: The present invention provides processes for the manufacturing of polypeptide conjugates. In particular, the invention provides methods for the purification of polypeptide conjugates, which include at least one polymeric modifying groups, such as a poly(alkylene oxide) moiety. Exemplary poly(alkylene oxide) moieties include poly(ethylene glycol) (PEG) and poly(propylene glycol). In an exemplary process, hydrophobic interaction chromatography (HIC) is used to resolve different glycoforms of glycoPEGylated polypeptides.
    Type: Grant
    Filed: October 3, 2007
    Date of Patent: March 3, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Shawn DeFrees, Kyle Kinealy
  • Patent number: 8962813
    Abstract: A process for manufacturing of a composition containing a purified factor for supporting wound healing selected from the group consisting of Hepatocyte Growth Factor (HGF) platelet derived growth factor (PDGF), Epidermal growth factor (EGF), transforming growth factor alfa (TGF-?), Transforming growth factor beta (TGF-?), insulin like growth factor (IGF-I) and Fibroblast growth factor (FGF) from sources, such as blood, containing the factor for supporting wound healing, wherein the manufacturing process comprises purification steps which are performed in the presence of antithrombin III (AT-III).
    Type: Grant
    Filed: January 25, 2007
    Date of Patent: February 24, 2015
    Assignee: Octapharma AG
    Inventors: Andrea Neisser-Svae, Stefan Winge, Anna Mjärdestam
  • Publication number: 20150045542
    Abstract: Methylglyoxal (MGO)-modified recombinant TNF-alpha antibodies (e.g., Adalimumab) are identified. MGO modification decreases binding between Adalimumab and TNF-alpha. Methods are disclosed for reducing the presence of MGO-modified antibodies in the production of Adalimumab TNF-alpha antibodies.
    Type: Application
    Filed: October 23, 2014
    Publication date: February 12, 2015
    Inventor: CHRIS M. CHUMSAE
  • Patent number: 8952137
    Abstract: A method is provided for producing soluble thrombomodulin substantially not containing a denatured product of the soluble thrombomodulin that is generated under acidic conditions, which comprises: subjecting the soluble thrombomodulin-containing material to an anion exchanger or hydroxyapatite; and carrying out linear gradient elution, stepwise gradient elution, or gradient elution in which linear gradient elution is combined with stepwise gradient elution under separation conditions in which the denatured product of the soluble thrombomodulin can be separated, wherein the gradient is a salt concentration gradient, so as to obtain an elution fraction containing soluble thrombomodulin that does not substantially contain the denatured product of the soluble thrombomodulin, either (a) after the position of a fraction has previously been confirmed, or (b) while confirming the elution fraction.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: February 10, 2015
    Assignee: Asahi Kasei Pharma Corporation
    Inventor: Susumu Ohigashi
  • Patent number: 8945872
    Abstract: Expression vector systems are provided for increased production of a recombinant GDF-5 (rhGDF-5) protein. Also provided are transformed host cells that were engineered to produce and express high levels of rhGDF-5 protein. Methods for production and high expression of rhGDF-5 protein are disclosed herein. The methods of enhancing production and protein expression of rhGDF-5 protein as disclosed are cost-effective, time-saving and are of manufacturing quality.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: February 3, 2015
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: David S. Scher, Roger E. Harrington
  • Patent number: 8933205
    Abstract: The invention provides a process for preparing a cell-binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: January 13, 2015
    Assignee: ImmunoGen, Inc.
    Inventors: Yong Dai, Yong Wang, Shengjin Jin, Deborah H. Meshulam, Godfrey W. Amphlett
  • Patent number: 8933204
    Abstract: The invention relates to a novel, industrial-scale process for the purification of gamma-immunoglobulins (IgG) starting from plasma or fractions thereof. The method involves two chromatographic steps, i.e. a cation exchange capture chromatography, and then a polishing anion exchange chromatography, ensuring a highly purified end product, which contains no aggregates, and high yields. The process also involves a virus inactivation step by means of a solvent/detergent treatment to inactivate the viruses with a lipid envelope, and a virus removal step by nanofiltering to ensure the removal of the non-enveloped viruses.
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: January 13, 2015
    Assignee: Kedrion S.p.A.
    Inventors: Claudia Nardini, Andrea Morelli, Claudio Farina, Sabrina Esposito, Alessandra Lazzarotti, Arianna Petrucci
  • Patent number: 8921064
    Abstract: A naturally occurring or recombinant protein, especially a mutein of porcine urate oxidase (uricase), that is essentially free of large aggregates can be rendered substantially non-immunogenic by conjugation with a sufficiently small number of strands of polymer such that the bioactivity of the protein is essentially retained in the conjugate. Such conjugates are unusually well suited for treatment of chronic conditions because they are less likely to induce the formation of antibodies and/or accelerated clearance than are similar conjugates prepared from protein preparations containing traces of large aggregates.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: December 30, 2014
    Assignees: Mountain View Pharmaceuticals, Inc., Duke University
    Inventors: Merry R. Sherman, Mark G. P. Saifer, L. David Williams, Michael S. Hershfield, Susan J. Kelly
  • Patent number: 8921097
    Abstract: The present invention relates to a method of expressing an immunotoxin in Pichia pastoris strain mutated to toxin resistance comprising a) growing the Pichia pastoris in a growth medium comprising an enzymatic digest of protein and yeast extract and maintaining a dissolved oxygen concentration at 40% and above; and b) performing methanol induction with a limited methanol feed of 0.5-0.75 ml/min/IO L of initial volume during induction along with a continuous infusion of yeast extract at a temperature below 17.5° C., antifoaming agent supplied up to 0.07%, agitation reduced to 400 RPM, and the induction phase extended out to 163 h.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: December 30, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: David M. Neville, Jr., Jung-Hee Woo, Yuan-Yi Liu
  • Patent number: 8921518
    Abstract: The present invention provides a method for industrial-scale protein separation by reverse phase chromatography by use of a buffer system and an additional salt.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: December 30, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Daniel E. Rasmussen, Arne Staby, John Strikart Nielsen, Ole Schou
  • Patent number: 8912117
    Abstract: The present invention provides a chromatography packing material having improved flow rate characteristics and adsorption characteristics. In particular, the present invention provides a chromatography packing material suitable for separation and purification of immunoglobulin in the manufacture of antibody preparations. A porous cellulose gel, which is made by adding polysaccharides having a limiting viscosity of 0.21 to 0.90 dL/g to porous cellulose particles, the dry weight per unit volume of the porous cellulose gel being 1.06 to 1.40 times the dry weight per unit volume of the porous cellulose particles, is used. By adding a predetermined amount of polysaccharides having a predetermined limiting viscosity to porous cellulose particles, flow rate characteristics and adsorption characteristics can be improved.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: December 16, 2014
    Assignee: JNC Corporation
    Inventors: Yoshihiro Matsumoto, Yasuto Umeda, Shigeyuki Aoyama, Masami Todokoro
  • Patent number: 8911992
    Abstract: Removal of genomic DNA from biological samples using cation exchange is described.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: December 16, 2014
    Assignee: Bio-Rad Laboratories, Inc.
    Inventor: Peter S. Gagnon
  • Patent number: 8895707
    Abstract: Proteins, including monoclonal antibodies, that have been retained on hydroxyapatite resins for purposes of protein separation, purification, or both, are eluted from the resins by a elution buffer that contains controlled amounts of calcium and phosphate ions. The buffer allows elution to be performed in repeated runs at an acidic pH without deterioration of the resin.
    Type: Grant
    Filed: August 8, 2011
    Date of Patent: November 25, 2014
    Assignee: Bio-Rad Laboratories, Inc.
    Inventor: Larry J. Cummings
  • Patent number: 8889838
    Abstract: The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: November 18, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Wolfgang Teschner, Hans-Peter Schwarz, Ruth Madlener, Sonja Svatos, Azra Pljevljakovic, Alfred Weber
  • Patent number: 8889837
    Abstract: The invention is a method for the purification of mono-PEGylated erythropoietin using two cation exchange chromatography steps wherein the same type of cation exchange material is used in both cation exchange chromatography steps and a method for producing a mono-PEGylated erythropoietin in substantially homogeneous form.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: November 18, 2014
    Assignee: Hoffman-La Roche Inc.
    Inventors: Josef Burg, Klaus Reichert, Axel Schroth, Hartmut Schurig, Axel Wessner
  • Patent number: 8877904
    Abstract: Methods, kits and apparatuses for chromatography purification of antibodies are provided. In some embodiments, antibodies are purified by mixed mode chromatography that does not comprise hydroxyapatite (HT) or fluorapatite (FT). The mixed mode chromatography step is then followed by a HT/FT chromatography step.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: November 4, 2014
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Peter S. Gagnon, Hong Chen, Russ Frost
  • Publication number: 20140322217
    Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.
    Type: Application
    Filed: January 14, 2014
    Publication date: October 30, 2014
    Applicant: Xencor, Inc.
    Inventors: Gregory MOORE, Matthew Bernett, Rumana Rashid, John Desjarlais
  • Publication number: 20140302592
    Abstract: The present invention relates to a two-step method for the purification of divalent cation binding proteins with high yield and high purity on anion exchange resin materials, to divalent cation binding proteins obtainable by said method, and to a kit comprising means for carrying out said method.
    Type: Application
    Filed: October 12, 2012
    Publication date: October 9, 2014
    Inventors: Artur Mitterer, Meinhard Hasslacher, Christian Fiedler
  • Patent number: 8852585
    Abstract: The invention relates to a method of treating or preventing disease associated with ?-amyloid polypeptides comprising administration of an immunoglobulin preparation enriched in immunoglobulin M (IgM), and pharmaceutical compositions comprising such preparations.
    Type: Grant
    Filed: January 30, 2007
    Date of Patent: October 7, 2014
    Assignee: Grifols Therapeutics Inc.
    Inventors: Philip Scuderi, Jr., Afshin Safavi, Matthew G. Langevin
  • Patent number: 8846344
    Abstract: The present invention relates to a process for the purification of a glycoprotein comprising subjecting a liquid containing said glycoprotein to the steps of: a) reverse phase chromatography, b) size exclusion chromatography, and c) hydrophobic interaction chromatography. Also provided is a manufacturing process for producing a glycoprotein of interest.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: September 30, 2014
    Assignee: Glycotope GmbH
    Inventors: Steffen Goletz, Lars Stockl
  • Patent number: 8822643
    Abstract: The present invention provides a process for purifying FV starting from human plasma or a fractionation intermediate thereof, that is simple, scalable to the industrial level and relatively inexpensive compared to the methods described in the literature to date. The invention consists of the use of two anion exchange chromatography steps, the first of which has the purpose of separating the FV from the PTC component factors, while the second has the purpose of isolating the protein of interest from the majority of plasma proteins by means of selective interaction with the weak anion exchange support used. The process developed has also had a viral inactivation step and a viral removal step included, contributing to the safety of the final product obtained, without however significantly altering the process total recovery of FV, and without necessitating the introduction of additional steps for eliminating the inactivating agents used, thanks to the order in which the various steps are conducted.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: September 2, 2014
    Assignee: Kedrion S.p.A.
    Inventors: Paola Rossi, Ilaria Nardini, Pierangelo Giovacchini, Filippo Mori, Claudio Farina
  • Patent number: 8809510
    Abstract: A method for purification of complement Factor H from a complement Factor H containing source such as blood or blood plasma, in particular a caprylate precipitate of a Factor H containing source, which is e.g. obtained by addition of caprylate ions to fractions of blood or plasma, comprising the steps of: a) providing a Factor H containing source, in particular reconstitution of caprylate precipitate to provide a complement Factor H containing solution; b) performing a cation exchange chromatography in particular as first chromatographic step; c) performing an anion exchange chromatography; d) performing a hydroxyl apatite chromatography; e) followed by ultra/diafiltration to obtain a complement Factor H concentrate.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: August 19, 2014
    Assignee: Octapharma AG
    Inventors: Hubert Brandstaetter, Petra Schulz, Juergen Roemisch
  • Publication number: 20140228539
    Abstract: The invention relates to a process for separating acetylated proteins from unacetylated proteins. In particular, the invention relates to a process of using multimodal chromatography to separate acetylated proteins from unacetylated proteins. In the prior art, multimodal chromatography is used to isolate antibodies. The invention found that multimodal chromatography can be used in the separation of acetylated proteins from unacetylated proteins.
    Type: Application
    Filed: April 18, 2014
    Publication date: August 14, 2014
    Inventors: Kuo-Ming YU, Judy Huei-chuan CHOU, Jennifer Renee HOPP
  • Publication number: 20140220633
    Abstract: The current invention reports a method for the purification of a not-glycosylated, heterologous polypeptide, which has been recombinantly produced in a prokaryotic cell, wherein the method comprises three chromatography steps of which the first chromatography step selected from i) hydrophobic charge induction chromatography, or ii) hydrophobic interaction chromatography, or iii) affinity chromatography, or iv) ion exchange chromatography, the second chromatography step is selected from i) anion exchange chromatography, or ii) cation exchange chromatography, or iii) hydroxylapatite chromatography, or iv) hydrophobic interaction chromatography, and the a third chromatography step is selected from i) hydrophobic charge induction chromatography, or ii) anion exchange chromatography, or iii) cation exchange chromatography, or iv) hydrophobic interaction chromatography, whereby the first chromatography step is an affinity chromatography in case of polypeptides capable of interacting with metal ligands, the second c
    Type: Application
    Filed: April 7, 2014
    Publication date: August 7, 2014
    Inventors: Roberto Falkenstein, Birgit Weydanz, Nicole Fuehrler, Claudia Giessel, Sybille Gabel, Adelbert Grossmann, Friederike Hesse, Marc Pompiati, Andreas Schaubmar, Brigitte Kraemer
  • Patent number: 8795533
    Abstract: The current invention comprises a method for the regeneration of a cation exchange chromatography column.
    Type: Grant
    Filed: October 26, 2010
    Date of Patent: August 5, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Josef Burg, Klaus Reichert, Axel Schroth, Hartmut Schurig, Axel Wessner
  • Patent number: 8779110
    Abstract: The invention provides an efficient method of purification of a modified cytokine. The process includes the use of a chromatographic technique for the purification of the desired cytokine. The purified cytokine can be used as a therapeutic composition.
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: July 15, 2014
    Assignees: Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.
    Inventors: Chaiti Roy, Darshan Koticha, Vivek Arthanari
  • Publication number: 20140187758
    Abstract: The invention is drawn to a method for purifying membrane-bound proteins expressed in recombinant insect cells using N-laurosarcosine. The invention is particularly suited for expressing cadherin-type receptors cloned from Ostrinia nubilalis, European Corn Borer, and expressed in Sf9 insect cells. The method is optionally adapted for use with 6-his tag proteins.
    Type: Application
    Filed: December 27, 2013
    Publication date: July 3, 2014
    Applicant: Dow AgroSciences LLC
    Inventors: James M. HASLER, Jianquan LI, Joel J. SHEETS
  • Publication number: 20140179904
    Abstract: The present invention provides methods for purifying proteins. In particular, the methods employ a two-step non-affinity chromatography process without the use of an in-process tangential flow filtration step.
    Type: Application
    Filed: February 28, 2014
    Publication date: June 26, 2014
    Applicant: Medarex, L.L.C.
    Inventors: Alahari Arunakumari, Gisela Maria Marques Ferreira
  • Publication number: 20140148585
    Abstract: The present invention relates to protein purification. More particularly, a method for directly recovering an objective protein from a protein composition and purifying a protein with a desired quality in a rapid and efficient manner is provided. Further, a rapid purification method capable of efficiently removing impurities included in the protein composition is provided. Therefore, compared to the conventional purification methods, quality and yield of the protein can be remarkably improved.
    Type: Application
    Filed: June 28, 2012
    Publication date: May 29, 2014
    Inventors: Tsutomu Sugihara, Tomoko Isoda, Yuya Taniguchi, Hidetaka Nomura, Toshiyuki Suzawa
  • Patent number: 8729244
    Abstract: The invention relates to a method for purifying factor B, comprising the steps consisting in: (i) obtaining a blood plasma fraction containing factor B; (ii) subjecting the fraction obtained in step (i) to a heparin-like affinity chromatography; (iii) subjecting the factor B-enriched fraction obtained in step (ii) to a cation exchange chromatography; (iv) subjecting the factor B-enriched fraction obtained in step (iii) to an anion exchange chromatography, (v) eluting the factor B.
    Type: Grant
    Filed: November 15, 2010
    Date of Patent: May 20, 2014
    Assignee: Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventor: Michel Poulle
  • Patent number: 8710196
    Abstract: A method for purifying a polypeptide by ion exchange chromatography is described in which a gradient wash is used to resolve a polypeptide of interest from one or more contaminants.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: April 29, 2014
    Assignee: Genentech, Inc.
    Inventors: Jefferson C. Emery, Paul J. McDonald, Rhona O'Leary
  • Patent number: 8703123
    Abstract: Provided is a method of obtaining biologically active recombinant human G-CSF from inclusion bodies, wherein the solubilization and refolding process can be performed at ambient temperature and the purification step comprises reversed phase chromatography (RP), in particular RP-HPLC. The G-CSF preparation so obtained is characterized by high purity and homogeneity.
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: April 22, 2014
    Assignee: BioGeneriX GmbH
    Inventors: Walter Hinderer, Christian Scheckermann
  • Patent number: 8703706
    Abstract: The present invention relates to a closed container holding a composition of an activated Factor VII polypeptide in an amount of in the range of 2.5-90 mg per imL volume of the container. The invention also relates to various processes for the preparation of such closed containers, a kit including such containers and a method of using the kit.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: April 22, 2014
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Anne Charlotte Arentsen, Per Kaersgaard